



ACNP Bulletin

American College of Neuropsychopharmacology 545 Mainstream Drive, Suite 110, Nashville, TN 37228-1201
Tel: 615-324-2360 • Fax: 615-324-2361 • E-mail: acnp@acnp.org • www.acnp.org

February 2007

Volume 13, Issue 1


In this issue:

President's Letter	1-2
Journal Update	2
Panel Submissions	3
Teaching Session Report	3
Dates to Remember	3
Honorific Awards	4
New Officers and Council	4
History Committee Needs Volunteers	4
New Members and Promotions	5
Travel Awardees	5
Annual Meeting Photos	6
Upcoming Meetings	7
In Memoriam	8

ACNP President's Letter

Dear Fellow Members,

Recently we lost a dear friend. Oakley Ray gave so much of himself for so many years to the ACNP. He cared deeply for the College and for the members. He was the face of the ACNP to the outside world. He was mentor, leader, supporter and friend to all who assumed responsibility for aspects of the College's functions. He was the "go to" person for any question, concern, or ideas for change. I talked at length with Oakley before agreeing to being nominated for president-elect, and again as my turn to serve approached. In his last comment to me, he said that he would miss the chance to work with me during my presidential year. I was touched by the comment at the time, and it brings a tear as I think of him now. We all owe much to Oakley's care of us and our College. His death on February 7 is a profound loss.



Will Carpenter
ACNP President, 2007

There is no easy transition to the remainder of this letter, but I wish to communicate a few thoughts concerning 2007. I hope 2007 will be another joyous and successful year for the ACNP and all of its members. During 2006 Ken Davis was a wise and decisive president as the College was faced with complex and critically important issues. We had a very successful 2006 meeting in a new locale, effected a successful transition in Journal leadership, and achieved each of the goals established for year 2 of the strategic plan. A new standard for conduct of supporting corporations was developed and enacted, and our Code is now viewed as a model for other professional colleges and societies. A new conflict of interest reporting format was adopted to provide more meaningful information, and reporting has been extended to elected Officers & Council and members of Publications, Ethics and Program Committees. There was much more, of course, some of which is mentioned below. I will take this opportunity to say "thank you" to Ken on behalf of the College, and to express my personal appreciation to Ken for his wonderful leadership. We also have a terrific leader in Ronnie Wilkins, and tremendous support from him and our ACNP staff.

The purpose of this letter is to inform the membership of a few of the challenges and opportunities for 2007.

Encouraged by the favorable response to the 2006 meeting location, the meeting in Boca Raton will help determine if south Florida locations work for the College. The financial side of the equation is good, and this is important in meeting the strategic goal of reducing the proportion of College funds received from commercial sources.

The College is launching a new publication, *Neuropsychopharmacology Reviews*, with Husseini Manji and Peter Kalivas as series editors. We hope to highlight this initiative at the 2007 Annual Meeting.

The AAMC has invited the College to present the Corporate Code of Conduct in a one-day workshop to the Council of Academic Societies in November. AAMC sees our Code of Conduct for Supporting Corporations as potentially a model for other societies.

(continued on page 2)

Council decided to end the three-year experiment with archiving the meeting abstracts. Throughout our history we have not archived abstracts from the annual meeting. However, in 2003 Council made a decision to conduct a three-year trial of archiving the abstracts and then re-evaluate that policy. In 2004-2006 the abstracts were published as a supplement to the December issue of *Neuropsychopharmacology*. In its December 2nd meeting, Council discussed the results of the three-year trial policy and decided that the benefits of archiving the abstracts do not outweigh the additional risks and disadvantages. Having the abstracts ready to publish along with the December issue of the journal has meant that we had to move our submission deadlines much earlier in the year. Also, publishing the abstracts potentially increases our legal liabilities by adding the ACNP imprimatur to them. Council noted that the primary benefit of the archival experiment has been the additional review of abstracts by the program committee and the journal editorial team. Therefore, Council made the decision to end the trial policy of archiving abstracts effective with the 2007 meeting, but to maintain the additional review of all abstracts, including poster abstracts, by the program committee.

The College is still determining the most effective and appropriate role to take in providing the public with information, and attempting to inform and influence public policy. We will publish position papers on the use of anti-psychotic drugs in the elderly, co-sign a report on anti-psychotic drugs and the metabolic syndrome, and continue the initiative on post-marketing detection of rare adverse events.

A sub-committee of the Liaison Committee will convene a one-day meeting in May with the objective of defining the impediments to drug development in the area of alcohol and substance abuse treatment. Hopefully, this meeting will start a dialogue between academic scientists, government agencies, and the pharmaceutical industry that might result in eliminating or minimizing those impediments.

In 2007 we need to establish effective procedures for monitoring the Code of Conduct for Supporting Corporations and for identifying and resolving potential conflicts identified with the new reporting procedures for members in certain elected and appointed positions.

2007 will likely bring continued intense activity for the Ethics Committee, and we must establish procedures that limit adjudication of complaints to those directly involving College activities [e.g., our meeting and our publications and official acts on behalf of the College]. Serious violation by members of our ethics code in affairs external to the College should only be brought to ACNP after investigation and judgment by that member's institution or some other responsible body. Maintaining ACNP core values of integrity and collegiality in the context of greatly increased filing of complaints is a challenge that must be successfully addressed.

Initiated during 2006, we hope to bring to fruition an IOM study and report to guide the general field of medical research on the rules of engagement between academic and government scientists and commercial entities.

An issue raised during the 2006 Issues in Ethics plenary session merits further attention by the College. I hope to find a format to explore the problems faced by industry as they address influential academic leaders' requests and demands. This side of the coin has received little attention to date.

The College will formally examine and update the strategic plan during the spring and summer. Remarkable changes have occurred during the first two years of the plan [we are now in year 3 and appear to be on target with most of the goals]. Major achievements include the committees becoming the work centers with Council assuming a more executive function and the substantial reduction in financial dependence.

These are a few of the specific goals for 2007. More generally, I hope that 2007 is a year of continued excellence in our meeting and publications, that we find the optimal degree of openness, transparency, and discretion to assure integrity in our operations and collegiality in our transactions.

***Neuropsychopharmacology* Vision and Goals**

James Meador-Woodruff, Editor, *Neuropsychopharmacology*



I am honored to have been selected by the College as the next editor of *Neuropsychopharmacology*. The journal is now in its 20th year, and is one of the most prestigious journals in the various fields in which we all work. For 2005, the journal's impact factor was 5.369, placing it 5th of 94 journals in psychiatry, 19/198 in neuroscience, and 14/187 in pharmacology. We are likely on track this year to reach 1000 annual submissions for the first time. The journal is by all means healthy, having steadily improved on each of my predecessors' watch. My pledge to you is that I will continue to build on this impressive base and take the journal to the next level.

In the short term, the new editorial team has assumed responsibility for the journal, and hopefully this process has gone smoothly for any of you that have papers under consideration. For those of you that had submitted papers prior to the change in editorship which effectively took place during our 2006 annual meeting, rest assured that your papers have been and are being handled by the field editor that you originally submitted through, although we are near the end of that transition.

We have made a number of changes around how manuscripts are handled centrally, including assignment of handling editors. We have begun a process of identifying manuscripts unlikely to be publishable in the journal, and have started a triage process to not delay
(continued on page 7)

Panel Submissions—New Categories

The Program Committee for 2006 recently announced new categories for Panel Submissions for the 2007 ACNP Annual Meeting, December 9-13, in Boca Raton, Florida. The call for proposals will be emailed to the membership in mid-February. The deadline for proposals is April 29, 2007. All proposals will be grouped by category. When submitting your proposal, please select a primary category and a secondary category, if applicable. These new categories will better classify the proposals for the Program Committee's review.

Primary categories:

Cellular and molecular neurobiology
Clinical trials
Cognitive neuroscience
Drug side effects
Epidemiology
Ethics
Genetics: animals
Genetics: humans
Human neurochemistry
Imaging
Non-pharmacological therapies
Novel methodologies/tools
Pharmacology: clinical
Pharmacology: pre-clinical
Phenomenology
Physiology: cellular
Physiology: in vivo
Training

Secondary categories (diseases):

Not applicable
Adjustment disorders
Anxiety disorders
Delirium, dementia and amnesic and other cognitive disorders
Disorders usually first diagnosed in infancy, childhood or adolescence
Dissociative disorders
Eating disorders
Factitious disorders
Impulse disorders not elsewhere classified
Mental disorders due to a general medical condition
Mood disorders
Personality disorders
Schizophrenia and other psychotic disorders
Sexual and gender identity disorders
Sleep disorders
Somatoform disorders
Substance-related disorders
Other medical disorders
Other neurological disorders
Other psychiatric disorders in late life
Other

Report from "Teaching Neuropsychopharmacology" Ira Glick, Chair Education & Training Committee

On Sunday, December 3, 2006, the 6th Annual Teaching Session, "Teaching Neuropsychopharmacology," was held with an estimated audience of 75-100 ACNP teachers and travel awardees.

The aim of these sessions has been to improve the clinical practice of psychopharmacology through more effective teaching. Past sessions have focused on content, curriculum, issues associated with various target constituencies and techniques of teaching.

This year the focus was on the "pearls," i.e., strategies and techniques of teaching psychopharmacology by those widely recognized as outstanding teachers. The areas covered were adult psychiatric residency training, child and adolescent psychiatry, CME formats, and teaching clinicians in various settings. The objective was to pass on to psychopharmacology teacher-members of the ACNP, lessons learned on the "field of battle." The format was short presentations with a great deal of audience interaction (questions, comments, and strategies that have worked in local settings).

The presentations included:

- Curriculum and Patient Based Teaching
Eric Peselow
- Teaching Child Psychopharmacology
Karen Wagner
- Teaching Geriatric Psychopharmacology
Carl Salzman
- Teaching Psychopharmacology in CME Settings
James Jefferson
- Teaching Neuroscience to Clinicians
Stephen Stahl

Overall, there was a great deal of pedagogic wisdom transmitted. Handouts illustrating some of the teaching points were distributed. The session will be submitted for publication in a psychopharmacology journal.

Dates to Remember

- Mid-February 2007 — Call for Proposals emailed
- April 29, 2007 — Deadline for Proposals
- April 30, 2007 — Deadline for Travel Award Applications
- May 4, 2007 — Minority Faculty Research Fellowship Deadline
- Mid-May 2007 — Registration Materials Mailed
- May 18, 2007 — Deadline for Honoric Awards Nominations

Annual Meeting 2006—Honorific Awards

The Julius Axelrod Mentorship Award was presented to George K. Aghajanian, M.D., Connecticut Mental Health Center. This award honors an ACNP member who has made an outstanding contribution to neuropsychopharmacology by mentoring and developing young scientists into leaders in the field. Dr. Aghajanian has worked diligently to develop his trainees into prominent scientists.



The Daniel H. Efron Research Award was awarded to David W. Self, Ph.D., UT Southwestern Medical Center. The Efron Award goes to an individual on the basis of outstanding basic/translational research contributions to neuropsychopharmacology. The selection is based on the quality of the contribution and its impact in advancing the field. Dr. Self was chosen for his work on the complex interaction between drug-induced neuroadaptations and their role in behavioral changes that characterize addiction.



The Joel Elkes Research Award was presented to Andreas S. Meyer-Lindenberg, M.D., Ph.D., BSc, National Institute of Mental Health. This award recognizes an outstanding clinical/translational contribution to neuropsychopharmacology and may be based on a single discovery or a cumulative body of work. Dr. Meyer-Lindenberg's work on the neurobiology of cognition with relevance to psychiatric disorders is highly innovative with the potential for high impact in the field.




The ACNP Media Award honors a member of the print or electronic media who has provided complete, accurate, and unbiased information about brain diseases to our society. Bill Lichtenstein, president, Lichtenstein Creative Media, was selected to receive this year's award for his contributions in educating the public about neuroscience, brain disorders and treatment advances through production of public television and radio programs and documentary films. Visit <http://www.lcmedia.com> for more information.



New 2007 Officers and Council Members

William T. Carpenter, Jr., M.D., Director, Maryland Research Psychiatric Center and Professor of Psychiatry and Pharmacology, University of Maryland, Baltimore, is the 2007 ACNP President.



Judith L. Rapoport, M.D., Chief, Child Psychiatry Branch, National Institute of Mental Health, Bethesda, MD, assumed the role of President-Elect.



John H. Krystal, M.D., Deputy Chairman for Research, Yale University School of Medicine, West Haven, CT, is a new member of Council.



David R. Rubinow, M.D., Chairman of Psychiatry, University of North Carolina, Chapel Hill, is also a new Council member.



History Committee Looking for Volunteers

The History Committee has begun editing video and audio transcripts from the ACNP archives of member interviews from past Annual Meetings. These interviews tell the history of neuropsychopharmacology and the College through the eyes of our membership. Tom Ban is heading up this project which will play a role in commemorating the 50th Anniversary of the College in 2011. If you are available to assist in editing the already transcribed interviews, please contact Kay White in the ACNP Executive Office at kwhite@acnp.org.

ACNP New Members/Promotions

The College elected 33 new Members and 15 Associate Members during the 2006 Annual Meeting. Three Members were promoted to Fellow, and one Foreign Corresponding Fellow was also elected.

New Members - 2007

James Abelson	Martin Paulus
Meenakshi Alreja	Bradley Peterson
Charles Beasley, Jr.	Joseph Piven
Sabina Berretta	Marc Potenza
Cynthia Bethea	Mark Rapaport
David Bredt	Natalie Rasgon
Alan Brown	Jeffrey Rausch
Vince Calhoun	Delbert Robinson
Charles Chavkin	Gerard Sanacora
Wilson Compton	Sanjaya Saxena
Stan Floresco	Larry Seidman
Jay Gingrich	Steven Siegel
Richard Lane	Jair Soares
Marco Leyton	Rikki Waterhouse
Emeran Mayer	Jeffrey Witkin
Andreas Meyer-Lindenberg	Robert Zipursky
Alexander Neumeister	

Associate Members – 2007

Vaishali Bakshi	Carl Hart
Christina Barr	F. Andrew Kozel
Zubin Bhagwagar	Rita Fuchs Lokensgard
Michael Detke	Ziad Nahas
Marlene Freeman	David Posey
Joseph Friedman	Wynne Schiffer
David Glahn	Naomi Simon
Margaret Haney	

Promotions - Member to Fellow

William Hargreaves
Richard Keefe
Patricio O'Donnell

Foreign Corresponding Fellow

W.W. Fleischhacker

2006 Travel Awardees

Forty-two travel awardees attended the 2006 Annual Meeting in Hollywood, Florida. The total included five Sanofi-Aventis Travel Awardees, five NIMH Travel Awardees, twenty ACNP Young Investigator Memorial Awardees, five Anxiety Disorders Association of America Travel Awardees, three from the APA Program for Minority Research, one Pfizer Awardee and three Minority Faculty Fellows. Following are the awardees (mentors in parentheses): Lily Alvarez-Jaimes (Cameron Carter), Deidre Anglin (Nina Schooler), Isabel Arrillaga-Romany (Theresa Branchek), Alasdair Barr (Victoria Arango), Katja Beesdo (Ira Glick), Theresa Buckley (Robert Rubin), Katherine Burdick (James Kennedy), Ricardo Caceda (Neal Swerdlow), Vince Calhoun (Eric Hollander), R. Andrew Chambers (Elliot Stein), Andrew Chen (J. Dee Higley), Sarah Clinton (Myrna Weissman), Loubna Erraji-Benchekroun (Edward Domino), Andrew Gilbert (Francisco Castellanos), John Hettema (Walter Brown), Brian Hitsman (Alan Green), Shailesh Jain (Sarah Lisanby), Carrie John (Anthony Grace), Amy Krain (Cynthia Kuhn), Angeli Landeros-Weisenberger (Uma Rao), Bernard Le Foll (Deborah Deas), Francis McClernon (Arthur Brody), Edward Meloni (Lisa Gold), Michael Minzenberg (Judith Rapoport), Gretchen Neigh (Gwenn Smith), Dost Ongur (Robert Innis), Ketema Paul (Joseph Takahashi), Koraly Perez-Edgar (Christine Marx), Michael Peterson (Suzanne Haber), Christopher Pittenger (Katharine Phillips), Brooks Pond (John Gilmore), Madhuri Roy (Darryle Schoepp), Elizabeth Santa Ana (Peter Kalivas), Edwin Santini (Michael Davis), Philip Shaw (Anantha Shekhar), Ravi Singareddy (Frank Yocca), Kimberly Stigler (Harriet de Wit), Isabel Sumaya (Margarita Dubocovich), Kenira Thompson (Gregory Quirk), Carlos Tirado (Cynthia Kuhn), Kuei-Yuan Tseng (Dolores Malaspina), Paula Ulery (William Carlezon).



Annual Meeting 2006



Annual Meeting 2006



authors from seeking a more appropriate or more likely place to publish, and importantly to be maximally efficient when requesting our reviewers' time by only sending to them those manuscripts that are more likely to eventually be in contention for our limited number of pages. I have rapidly discovered that the most limited resource we have at our disposal is reviewers. My personal thanks to those of you to whom I have already turned repeatedly for your thoughtful (and speedy) reviews.

I have instituted a weekly editorial conference call for the deputy editors and our managing editor, Jen Mahar, where these triage decisions and other issues are discussed. We are also implementing changes to reduce the time a manuscript is in review. My goal is to further decrease the time from initial submission to an author being notified of an editorial decision, to carve additional days from the already relatively short time the last editorial team had been able to accomplish. Many of these changes should be behind the scenes for authors, but the outcome is that authors will get ever faster reviews and decisions.

Longer term, a number of new initiatives are under discussion. One area that is evolving for all of medicine is the issue of disclosure of potential conflicts of interest. This is clearly an area of intense interest and is a changing landscape. With the guidance of the Publications Committee, I feel we have streamlined the journal's disclosure policy as much as we can given current trends and mandates from the College, and that what authors need to provide should be relatively straightforward.

We are one of the few top notch journals in any of our fields that does not have word limits: while our average paper runs 8 or so pages in print, we have some considerably longer than this but not many shorter. Given our fixed number of pages, we will need to institute policies on manuscript length in the near future.

I am particularly interested in developing an electronic-only eNeuropsychopharmacology website, hopefully in collaboration with Nature, our publisher, to publish negative studies. We all have well designed studies that result in negative data that should be published but are often given low priority at journals simply because they are negative. Hopefully we will be able to implement something along these lines this year.

Much of what has made *Neuropsychopharmacology* great has not and will not change on my watch. We will keep the current cover layout, so please send us any attractive figures that you would like considered as a cover illustration. Over the past 20 years, I have personally heard every editor of the journal ask the membership to keep *Neuropsychopharmacology* in mind as a place to send some of your best work. I now ask you to do the same: this is our journal, and as we continue to develop, be increasingly prominent, and grow our impact factor, submissions from our membership can and should lead the way. I am always happy to hear from you and get feedback on what we are doing well as well as what we could do better. Again, I am honored to have been selected for this position, and look forward to continuing to serve the ACNP in this role.

Upcoming Meetings



8th International Conference on AD/PD

March 14 - 18, 2007
Salzburg, Austria
Secretariat:
Kenes International
Tel: +41 22 908 0488
Fax: +41 22 732 2850
www.kenes.com/adpd
adpd@kenes.com

62nd Annual Convention Society of Biological Psychiatry

May 17th-19th, 2007
Westin Horton Plaza
San Diego, CA
Peterson.maggie@mayo.edu
<http://www.sobp.org/>

APA

May 19-24, 2007
2007 Annual Meeting
San Diego, CA
<http://www.psych.org/>
apa@psych.org

CCNP

June 15-18, 2007
30th Annual Meeting
Banff, Alberta, Canada
www.ccnp.ca

World Congress on Psychiatric Genetics

October 7-11, 2007
Marriott Marquis Hotel
New York, NY
www.wcpg2007.com

20th ECNP Congress

October 13 - 17, 2007
Vienna, Austria
ecnp2007@iceo.be

ACNP Annual Meeting

December 9-13, 2007
Boca Raton Resort and Club
Boca Raton, FL
www.acnp.org
acnp@acnp.org

Annual Meeting 2006



Past Presidents' Luncheon 2006



Seated: George Simpson, Jonathan Cole, Don Klein, Biff Bunney, Ken Davis, Will Carpenter, Joe Coyle

Standing: Ronnie Wilkins, Herb Meltzer, Roger Meyer, Chuck O'Brien, Steve Bunney, David Kupfer, Dennis Charney

In Memoriam



Oakley S. Ray
1931—2007

ACNP Executive Secretary
1979—2005

“Oakley was the face of the ACNP for most of the world.”

Will Carpenter
ACNP President

American College of Neuropsychopharmacology

545 Mainstream Drive, Suite 110
Nashville TN 37228-1201

Tel: 615-324-2360
Fax: 615-324-2361
E-mail: acnp@acnp.org

We're on the web
www.acnp.org